ENDONOVO THERAPEUTICS, INC.
ENDONOVO THERAPEUTICS, INC.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
Cash | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | |||||
Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | ||||||||||||||||||
Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Receivable Net Current | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deposits Assets Current | - | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Finite Lived Intangible Assets Net | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | |||||
Assets | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | |||||
Liabilities And Stockhold… | ||||||||||||||||||
Accounts Payable Current | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Interest Payable Current | - | - | - | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | |||||
Accounts Payable And Accrued Liabilities Current | - | - | 1 | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities Current | ||||||||||||||||||
Liabilities Current | 24 | 23 | 25 | 33 | 21 | 21 | 20 | 18 | 20 | 19 | 18 | 17 | 15 | |||||
Deferred Compensation Liability Current | - | - | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | |||||
Notes Payable Current | - | - | - | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | |||||
Notes Payable Related Parties Classified Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Derivative Liabilities Current | 6 | 6 | 9 | 17 | 5 | 5 | 5 | 3 | 6 | 6 | 5 | 4 | 3 | |||||
Other Liabilities Noncurrent | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | |||||
Business Combination Contingent Consideration Liab… | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | - | - | - | 0 | - | |||||
Liabilities | 24 | 23 | 26 | 33 | 21 | 21 | 20 | 18 | 20 | 19 | 18 | 17 | 15 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 44 | 44 | 44 | 43 | 42 | 42 | 41 | 41 | 41 | 40 | 40 | 39 | 39 | |||||
Stockholders Equity | ||||||||||||||||||
Common Stock Share Subscribed But Unissued Subscri… | - | - | - | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Stockholders Equity | -23 | -22 | -24 | -32 | -20 | -19 | -18 | -16 | -18 | -17 | -16 | -14 | -13 | |||||
Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Stockholders Equity Note Subscriptions Receivable | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - | - | |||||
Retained Earnings Accumulated Deficit | -67 | -66 | -68 | -75 | -62 | -61 | -59 | -56 | -59 | -57 | -56 | -53 | -51 | |||||
Liabilities And Stockholders Equity | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | |||||
Allowance For Doubtful Accounts Receivable Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Debt Instrument Unamortized Discount Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | |||||
Common Stock Shares Authorized | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | |||||
Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Common Stock Shares Issued | 319 | 279 | 270 | 213 | 159 | 150 | 81 | 74 | 69 | 61 | 52 | 25 | 17 | |||||
Shares Outstanding | 319 | 279 | 270 | 213 | 159 | 150 | 81 | 74 | 69 | 61 | 52 | 25 | 17 | |||||
Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -15.38% | -24.18% | -45.05% | -6.64% | -13.45% | 3.36% | 2.30% | -54.48% | -59.77% | - | - | - |
| 2022 | 33.54% | -1.75% | -12.76% | 0.00% | 0.00% | 0.00% | 58.55% | 75.54% | 111.44% | -14.77% | -18.27% | -10.10% |
| 2021 | 0.33% | 15.51% | -10.23% | -5.89% | 17.58% | -23.39% | -1.16% | 44.01% | 4.65% | -36.84% | -57.89% | -47.37% |
| 2020 | - | - | - | - | - | - | - | - | - | 21.94% | -0.97% | 35.00% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | ||||||||||||||||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |||||
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | |||||
| Working Capital | -23.66M | -23.06M | -25.39M | -33.37M | -20.95M | -20.67M | -19.71M | -17.61M | -20.21M | -19.14M | -18.22M | -16.78M | -15.33M | |||||
Leverage & Debt | ||||||||||||||||||
| Debt to Equity | -1.04 | -1.05 | -1.05 | -1.04 | -1.07 | -1.08 | -1.10 | -1.13 | -1.12 | -1.13 | -1.16 | -1.18 | -1.21 | |||||
| Interest Coverage TTM | -2.15 | -2.08 | -2.55 | -2.47 | -2.55 | -2.92 | -2.28 | -2.36 | -2.00 | -1.92 | -1.77 | -1.40 | -0.78 | |||||
| Debt Ratio | 29.15 | 22.88 | 21.33 | 26.12 | 14.51 | 13.01 | 10.94 | 8.86 | 9.53 | 8.47 | 7.33 | 6.51 | 5.67 | |||||
Efficiency & Turnover | ||||||||||||||||||
| Asset Turnover TTM | 0.23 | 0.20 | 0.15 | 0.08 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.05 | 0.05 | 0.06 | 0.10 | |||||
| Days Sales Outstanding TTM | - | - | 3.36 | - | 103.22 | 171.32 | 37.79 | 4.71 | 17.39 | 16.23 | 14.73 | 26.07 | 7.37 | |||||
| Receivables Turnover TTM | - | - | 108.54 | - | 3.54 | 2.13 | 9.66 | 77.52 | 20.98 | 22.49 | 24.78 | 14.00 | 49.56 | |||||
Per Share Metrics | ||||||||||||||||||
| Diluted EPS TTM | -0.00 | -0.00 | -0.01 | - | -0.02 | -0.03 | -0.04 | - | -0.11 | -0.12 | -0.18 | - | -0.25 | |||||
| Free Cash Flow Per Share TTM | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | -0.03 | -0.05 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | ||||||||||||||||||
| Gross Profit Margin TTM | 96.21% | 95.14% | 93.98% | 92.62% | 1.57% | -18.33% | 67.60% | 79.50% | 36.92% | 56.36% | 52.89% | 60.57% | 78.37% | |||||
| Operating Profit Margin TTM | -1,023.16% | -995.78% | -1,499.40% | -2,411.69% | -22,206.38% | -30,354.78% | -5,217.02% | -3,045.68% | -3,009.54% | -2,396.36% | -2,157.85% | -1,756.49% | -977.15% | |||||
| Net Profit Margin TTM | -1,722.23% | -1,599.52% | -4,002.99% | -13,649.17% | -22,145.06% | -36,842.58% | -6,975.86% | -4,247.17% | -8,935.37% | -6,075.69% | -5,667.74% | -238.60% | -1,331.11% | |||||
Growth Metrics | ||||||||||||||||||
| Net Revenue Growth (1Y) | 1,699.85% | 2,302.27% | 442.42% | 85.15% | -83.14% | -90.52% | -68.91% | -55.91% | -72.16% | -63.23% | -60.94% | -46.55% | 48.51% | |||||
| Net Income Growth (1Y) | 39.98% | 4.29% | 211.26% | 495.02% | -58.22% | -42.54% | -61.74% | 684.89% | 86.90% | 62.06% | -29.85% | -97.72% | -60.75% | |||||
| EPS Growth (1Y) | -27.95% | -49.29% | -2.17% | 155.77% | -81.97% | -74.99% | -79.87% | 221.85% | -54.50% | -72.75% | -95.02% | -99.89% | -98.11% | |||||
Valuation Metrics | ||||||||||||||||||
| P/E TTM | -0.85 | -0.94 | -0.47 | -0.14 | -0.36 | -0.30 | -0.50 | -0.30 | -0.24 | -0.31 | -0.19 | -1.25 | -0.38 | |||||
| P/B TTM | -0.16 | -0.18 | -0.17 | -0.08 | -0.06 | -0.06 | -0.08 | -0.06 | -0.10 | -0.13 | -0.09 | -0.03 | -0.12 | |||||
| P/S TTM | 14.70 | 15.11 | 18.84 | 18.51 | 80.00 | 109.55 | 34.77 | 12.77 | 21.79 | 19.08 | 10.90 | 2.97 | 5.12 | |||||
| Market Cap | 3.76M | 4.01M | 4.16M | 2.51M | 1.14M | 1.21M | 1.41M | 933.45K | 1.84M | 2.22M | 1.43M | 493.19K | 1.55M | |||||
| Enterprise Value | 3.76M | 3.97M | 4.15M | 9.55M | 8.24M | 8.45M | 8.52M | 7.90M | 8.47M | 8.75M | 7.94M | 6.97M | 7.50M | |||||
Calculated Values | ||||||||||||||||||
| Free Cash Flow TTM | -629.90K | -688.40K | -729.04K | -678.84K | -844.59K | -890.14K | -819.59K | -986.58K | -788.14K | -715.41K | -734.32K | -741.59K | -857.12K | |||||
| Net Debt | 0.00 | -32.60K | -10.94K | 7.04M | 7.10M | 7.24M | 7.11M | 6.97M | 6.63M | 6.53M | 6.51M | 6.48M | 5.95M | |||||
Per-Share and Margin | ||||||||||||||||||
| EPS TTM | ||||||||||||||||||
| Adjusted EPS TTM | ||||||||||||||||||
| Cash Flow Per Share TTM | ||||||||||||||||||
| Pretax Margin TTM | ||||||||||||||||||
| Stock Comp to Revenue TTM | ||||||||||||||||||
Turnover Ratios and Averages | ||||||||||||||||||
| Average Assets | ||||||||||||||||||
| Average Equity | ||||||||||||||||||
| Average Inventory | ||||||||||||||||||
| Average Receivables | ||||||||||||||||||
| Average Accounts Payables | ||||||||||||||||||
| Inventory Turnover TTM | ||||||||||||||||||
| Payables Turnover TTM | ||||||||||||||||||
| Days Inventory Outstanding TTM | ||||||||||||||||||
| Days Payables Outstanding TTM | ||||||||||||||||||
| Cash Conversion Cycle TTM | ||||||||||||||||||
| Working Capital to Revenue | ||||||||||||||||||
| Deferred Revenue to Revenue | ||||||||||||||||||
Growth Rates | ||||||||||||||||||
| Total Assets Growth (1Y) | ||||||||||||||||||
| Total Assets Growth (3Y) | ||||||||||||||||||
| Total Assets Growth (5Y) | ||||||||||||||||||
| Dividends Paid Growth (1Y) | ||||||||||||||||||
| Dividends Paid Growth (3Y) | ||||||||||||||||||
| Dividends Paid Growth (5Y) | ||||||||||||||||||
| EPS Growth (3Y) | ||||||||||||||||||
| EPS Growth (5Y) | ||||||||||||||||||
| Net Income Growth (3Y) | ||||||||||||||||||
| Net Income Growth (5Y) | ||||||||||||||||||
| Net Profit Margin Growth (1Y) | ||||||||||||||||||
| Net Profit Margin Growth (3Y) | ||||||||||||||||||
| Net Profit Margin Growth (5Y) | ||||||||||||||||||
| Net Revenue Growth (3Y) | ||||||||||||||||||
| Net Revenue Growth (5Y) | ||||||||||||||||||
| Deferred Revenue Growth (1Y) | ||||||||||||||||||
| Retained Earnings Growth (1Y) | ||||||||||||||||||
Credit, Liquidity, Returns, Payout | ||||||||||||||||||
| Cash Ratio | ||||||||||||||||||
| Net Working Capital | ||||||||||||||||||
| Debt to EBITDA TTM | ||||||||||||||||||
| Net Debt to EBITDA TTM | ||||||||||||||||||
| Net Debt to Equity | ||||||||||||||||||
| Altman A | ||||||||||||||||||
| Altman B | ||||||||||||||||||
| Altman C | ||||||||||||||||||
| Altman D | ||||||||||||||||||
| Altman E | ||||||||||||||||||
| Altman Z-Score | ||||||||||||||||||
| ROA TTM | ||||||||||||||||||
| ROE TTM | ||||||||||||||||||
| NOPAT TTM | ||||||||||||||||||
| ROIC TTM | ||||||||||||||||||
| Effective Tax Rate TTM | ||||||||||||||||||
| Payout Ratio TTM | ||||||||||||||||||
| Dilution Ratio | ||||||||||||||||||
| Retained Earnings to Equity | ||||||||||||||||||
| Treasury Stock to Equity | ||||||||||||||||||
| Treasury Stock Change (1Y) | ||||||||||||||||||
| Accrued to Current Liabilities | ||||||||||||||||||
| NCAV | ||||||||||||||||||
| NCAV Per Share TTM | ||||||||||||||||||
Valuation Ratios | ||||||||||||||||||
| P/CF TTM | ||||||||||||||||||
| Dividend Yield TTM | ||||||||||||||||||
| Free Cash Flow Yield TTM | ||||||||||||||||||
| EV EBITDA TTM | ||||||||||||||||||
| EV EBIT TTM | ||||||||||||||||||
| Stock Compensation TTM | ||||||||||||||||||
| Adjusted Net Income TTM | ||||||||||||||||||
| Billings TTM | ||||||||||||||||||
| Total Debt | ||||||||||||||||||
| Invested Capital | ||||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
ENDONOVO THERAPEUTICS, INC. (ENDV) — SEC Financial Statements & Analysis
ENDONOVO THERAPEUTICS, INC. (ENDV) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. ENDONOVO THERAPEUTICS, INC. trades on OTC as: ENDV. Based on its latest SEC filing (Form 10-Q, period ending 2023-09-30), ENDONOVO THERAPEUTICS, INC. reported a 1699.85% year-over-year revenue growth, a Gross Profit Margin of 96.21% (TTM), a Debt-to-Equity ratio of -1.04x, a Price-to-Sales (P/S) ratio of 14.70x (TTM), a Price-to-Book (P/B) ratio of -0.16x (TTM), at a market cap of $3.76M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 1699.85%
- Gross Profit Margin TTM
- 96.21%
- Debt To Equity
- -1.04x
- P/S TTM
- 14.70x
- P/B TTM
- -0.16x
- Market Cap
- $3.76M
Data as of 2023-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ENDONOVO THERAPEUTICS, INC. in?
ENDONOVO THERAPEUTICS, INC. (ENDV) operates in the Electromedical & Electrotherapeutic Apparatus industry.
What is ENDV's market cap?
ENDONOVO THERAPEUTICS, INC. (ENDV) has a market capitalization of $3.76M as of 2023-09-30.
What exchange does ENDV trade on?
ENDONOVO THERAPEUTICS, INC. (ENDV) trades on the OTC.
Where is ENDONOVO THERAPEUTICS, INC. incorporated?
ENDONOVO THERAPEUTICS, INC. is incorporated in DE.